Evidence map›Paper›PMID 26271057›Full record

Trial reportJournal of the American College of Cardiology2015

Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial.

Vera Bittner, Marnie Bertolet, Rafael Barraza Felix, Michael E Farkouh, Suzanne Goldberg, Kodangudi B Ramanathan, J Bruce Redmon, Laurence Sperling, Martin K Rutter, BARI 2D Study Group

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American College of Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00006305 (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes), which is not on this map. Cited by 48 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 3 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00006305 phase3completednot on this map

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes

TypeinterventionalSponsorUniversity of PittsburghRan2000 to 2009Enrolled2,368ConditionsCoronary Disease, Cardiovascular Diseases, Heart Diseases, Insulin ResistanceArmsAngioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Coronary Artery Bypass, Biguanides, thiazolidinediones, Insulin, sulfonylurea, ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial.Journal of the American College of Cardiology · 2025
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Projected Impact of LDL-C and HbAJACC. Advances · 2026
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 3 countries.

Vera BittnerDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: vbittner@uab.edu.
Marnie BertoletDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
Rafael Barraza FelixMexican Institute of Social Security, Mexico City, Mexico.
Michael E FarkouhMount Sinai School of Medicine, New York, New York.
Suzanne GoldbergNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Kodangudi B RamanathanVA Medical Center Memphis, Memphis, Tennessee.
J Bruce RedmonDepartment of Medicine and Urologic Surgery, University of Minnesota, Minneapolis, Minnesota.
Laurence SperlingEmory University, Atlanta, Georgia.
Martin K RutterThe Endocrinology and Diabetes Research Group, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom; Manchester Diabetes Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
BARI 2D Study Group
Emory University · USIcahn School of Medicine at Mount Sinai · USManchester Academic Health Science Centre · GBMemphis VA Medical Center · USMexican Social Security Institute · MXNational Institutes of Health · USUniversity of Alabama at Birmingham · USUniversity of Minnesota · USUniversity of Pittsburgh · US

Funding

BARI II:Foreign RecruitmentU01HL061744 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KELSEY, SHERYL F · 2000 to 2009
$55.4M
BARI II - FIBRINOLYSIS AND COAGULATION COREU01HL063804 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI SOBEL, BURTON E · 2000 to 2006
$3.8M
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2U01HL061748 · NHLBI · STANFORD UNIVERSITY · PI HLATKY, MARK A. · 2000 to 2006
$2.6M
BARI II GRANT PROPOSAL FOR ECG CORE LABORATORYU01HL061746 · NHLBI · SAINT LOUIS UNIVERSITY · PI CHAITMAN, BERNARD R · 2000 to 2008
$1.6M
Treatment and Risk Factor Determinants of Cardiovascular Outcomes in BARI 2DR21HL121495 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BROOKS, MARIA MORI · 2013 to 2014
$222k
NHLBI NIH HHS R21 HL121495NHLBI NIH HHS U01 HL061744NHLBI NIH HHS U01 HL061746NHLBI NIH HHS U01 HL061748NHLBI NIH HHS U01 HL063804
6 · The paper itself

Abstract

backgroundIt is unclear whether achieving multiple risk factor (RF) goals through protocol-guided intensive medical therapy is feasible or improves outcomes in type 2 diabetes mellitus.

objectivesThis study sought to quantify the relationship between achieved RF goals in the BARI 2D (Bypass Angioplasty Investigation Revascularization 2 Diabetes) trial and cardiovascular events/survival.

methodsWe performed a nonrandomized analysis of survival/cardiovascular events and control of 6 RFs (no smoking, non-high-density lipoprotein cholesterol <130 mg/dl, triglycerides <150 mg/dl, blood pressure [systolic <130 mm Hg; diastolic <80 mm Hg], glycosylated hemoglobin <7%) in BARI 2D. Cox models with time-varying number of RFs in control were adjusted for baseline number of RFs in control, clinical characteristics, and trial randomization assignments.

resultsIn 2,265 patients (mean age 62 years, 29% women) followed up for 5 years, the mean ± SD number of RFs in control improved from 3.5 ± 1.4 at baseline to 4.2 ± 1.3 at 5 years (p < 0.0001). The number of RFs in control during the trial was strongly related to death (global p = 0.0010) and the composite of death, myocardial infarction, and stroke (global p = 0.0035) in fully adjusted models. Participants with 0 to 2 RFs in control during follow-up had a 2-fold higher risk of death (hazard ratio: 2.0; 95% confidence interval: 1.3 to 3.3; p = 0.0031) and a 1.7-fold higher risk of the composite endpoint (hazard ratio: 1.7; 95% confidence interval: 1.2 to 2.5; p = 0.0043), compared with those with 6 RFs in control.

conclusionsSimultaneous control of multiple RFs through protocol-guided intensive medical therapy is feasible and relates to cardiovascular morbidity and mortality in patients with coronary disease and type 2 diabetes mellitus. (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D]; NCT00006305).

Indexed as

AgedAngioplasty, Balloon, CoronaryCardiovascular DiseasesCoronary Artery BypassDiabetes Mellitus, Type 2FemaleFollow-Up StudiesHumansMaleMiddle AgedRisk FactorsSurvival Rateblood pressurecholesterolcoronary heart diseasediabetes mellitusglycosylated hemoglobin Asmoking

Identifiers

PMID26271057
PMCPMC4550809
OpenAlexW1469193822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.